...
首页> 外文期刊>Bioorganic and Medicinal Chemistry Letters >CoMFA and CoMSIA 3D-QSAR studies on S(6)-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) analogs as inhibitors of human equilibrative nucleoside transporter 1 (hENT1).
【24h】

CoMFA and CoMSIA 3D-QSAR studies on S(6)-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) analogs as inhibitors of human equilibrative nucleoside transporter 1 (hENT1).

机译:CoMFA和CoMSIA 3D-QSAR研究S(6)-(4-硝基苄基)巯嘌呤核糖核苷(NBMPR)类似物作为人类平衡核苷转运蛋白1(hENT1)的抑制剂。

获取原文
获取原文并翻译 | 示例
           

摘要

3D-QSAR (CoMFA and CoMSIA) studies were performed on human equlibrative nucleoside transporter (hENT1) inhibitors displaying K(i) values ranging from 10,000 to 0.7nM. Both CoMFA and CoMSIA analysis gave reliable models with q2 values >0.50 and r2 values >0.92. The models have been validated for their stability and robustness using group validation and bootstrapping techniques and for their predictive abilities using an external test set of nine compounds. The high predictive r2 values of the test set (0.72 for CoMFA model and 0.74 for CoMSIA model) reveals that the models can prove to be a useful tool for activity prediction of newly designed nucleoside transporter inhibitors. The CoMFA and CoMSIA contour maps identify features important for exhibiting good binding affinities at the transporter, and can thus serve as a useful guide for the design of potential equilibrative nucleoside transporter inhibitors.
机译:对3D-QSAR(CoMFA和CoMSIA)的研究是在人类平衡核苷转运蛋白(hENT1)抑制剂上进行的,其K(i)值在10,000至0.7nM之间。 CoMFA和CoMSIA分析均给出了q2值> 0.50和r2值> 0.92的可靠模型。使用组验证和自举技术对模型的稳定性和鲁棒性进行了验证,并使用九种化合物的外部测试集对模型的预测能力进行了验证。测试集的高预测r2值(CoMFA模型为0.72,CoMSIA模型为0.74)表明,该模型可以证明是预测新设计的核苷转运蛋白抑制剂活性的有用工具。 CoMFA和CoMSIA等高线图确定了对于在转运蛋白上表现出良好结合亲和力至关重要的特征,因此可以用作设计潜在的平衡核苷转运蛋白抑制剂的有用指南。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号